Temasek trims Celltrion stake despite stock slump

Singapore’s sovereign wealth fund pares down its stake in South Korea's leading biologic drug maker for the second time this year as it continues to restructure its investment portfolio.
Celltrion is likely to receive US FDA approval for biolsimilar drug Rituxan, also known as Truxima in Europe
Celltrion is likely to receive US FDA approval for biolsimilar drug Rituxan, also known as Truxima in Europe

Temasek raised W895 billion ($793 million) from another partial sale in South Korean biopharmaceutical firm Celltrion on Monday, moving quickly to sell the shares shortly after the lockup period for its previous sale expired last month

Through an accelerated bookbuild offering, Singapore’s sovereign wealth fund sold 3 63 million shares in the Korea-listed firm at W247,000 per share -- at the widest end of the marketed 5% to 8% discount range against the stock’s W268,500 Monday close  

Sources familiar with the situation said the transaction, which was made through Temasek’s subsidiary Ion Investments, was upsized from 3 39 million shares after being oversubscribed "multiple" times by institutional investors The final deal size equated to 2...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at [email protected], or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at [email protected], or +(852) 2122 5222